PrimaryMarkets welcomes you to the Imugene Investor Centre. We are actively supporting awareness and promotion of this ASX-listed biopharmaceutical company.
The Imugene Board of Directors have directed PrimaryMarkets to introduce Imugene to all those interested.
Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing various cancer immunotherapies. Their mission is to build
a pipeline of B-cell peptide cancer vaccines and therapeutics with lead products such as – HER-Vaxx – a proprietary therapeutic cancer immunotherapy
that stimulates a polyclonal antibody response. Imugene is also developing a B cell vaccine, KEY-Vaxx.
To view the Imugene share price, announcements, presentation/reports, commentary note, news and videos, please use the Imugene navigation bar on
the side panel.
Animoca Brands
Arbortech
Blooms the Chemist
Crestone
Federation Alternative Investments
Genex Power
Haoma Mining
Planet Innovation Holdings
PrimaryMarkets
VGW Holdings
Waratah Hotel Group
Sample Trading Hub
Zeotech
Capital Raises
Secondary Trading